Pfizer’s CTI Shows Tangible Signs Of Progress In Its Junior Year
Pfizer’s Centers for Therapeutic Innovation program has grown in less than three years to include 24 academic partners. First drug candidate to emerge from the research model is expected to enter the clinic this year, and Pfizer’s investment in CTI has grown.
You may also be interested in...
The partnership, announced Dec. 4, marks the first time a U.S. government agency has entered into a collaborative arrangement to conduct research through Pfizer’s Centers for Therapeutic Innovation network.
With three to four years in the books, Big Pharma’s updated tie-ups with academia have started to progress – some have even reached first-in-human stages, but these updated models have yet to produce any radical results that show they are an improvement over old-style partnerships.
The big pharma plays up its ability to work with external partners weeks after its attempted acquisition of AstraZeneca fell through. The new facility is part of its plan to increase ties between scientists.